MGI Pharma Drug Reduces Side Effect of Cancer Therapy
Posted on: Thursday, 18 January 2007, 12:00 CST
MGI Pharma has published data on its treatment for oral mucositis, a side effect of cancer therapies, suggesting that the drug Saforis reduced the incidence and severity of the disease in a phase III trial.
Saforis is an investigational therapy for the treatment and prevention of oral mucositis in patients receiving mucotoxic cancer therapy. The phase III trial of Saforis was conducted in patients with breast cancer who were receiving anthracycline-based chemotherapy regimens.
The primary endpoint of this trial, defined as a reduction in incidence and severity of oral mucositis, was met. Data from this study indicate that the incidence of oral mucositis was 38.7% in Saforis-treated patients compared to 49.7% in patients who received placebo. Overall, the data indicated that the safety profile of Saforis was comparable with that of placebo.
However, the FDA has requested an additional phase III trial of Saforis before it will approve the drug. MGI Pharma said it is currently evaluating options to maximize the value of Saforis.
Source: Datamonitor
Related Articles
- Biomodels' Oral Mucositis Expertise Speeds FDA Approval for ActoGeniX's Phase 1b Trial of AGO13 in Cancer Patients
- Arpida Publishes Top-Line Data of Phase II "Intravenous-To-Oral" Switch Trial With Oral Iclaprim
- TRACON Pharmaceuticals Doses the First Patient in a Phase 1 Clinical Trial With Oral TRC102, An Inhibitor of Chemotherapy Resistance, in Combination With Alimta
- Poniard Pharmaceuticals Announces Positive Preliminary Bioavailability Data From Ongoing Phase 1 Trial of Oral Picoplatin in Patients With Solid Tumors
- Ariad Initiates Phase III Trial of Oral Deforolimus
- ARIAD Initiates Phase 3 'Succeed' Trial of Oral Deforolimus in Patients With Metastatic Sarcomas
- Ariad Reaches Agreement With FDA for Phase III Cancer Drug Trial
- MGI PHARMA Announces Publication of Phase 3 Data for Saforis(TM) (Glutamine) Powder in UpTec(TM) for Oral Suspension in Cancer
- Exelixis Initiates Phase II Trial of XL880 in Patients With Gastric Cancer
- Cytokinetics Announces Initiation of Phase II Clinical Trial in Renal Cell Cancer and Phase I Clinical Trial in Pediatric Solid Tumors
 |
 |
User Comments (0)
RSS Feeds